↓ Skip to main content

Dove Medical Press

Article Metrics

A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients

Overview of attention for article published in OncoTargets and therapy, June 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (68th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

policy
1 policy source
twitter
1 tweeter

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
14 Mendeley
Title
A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients
Published in
OncoTargets and therapy, June 2016
DOI 10.2147/ott.s96830
Pubmed ID
Authors

Haipeng Xiao, Zijun Huo, Shuang Yu, Shubin Hong, Xiaopei Cao, Lingling Xiu, Zhihong Liao, Yanbing Li

Abstract

Vandetanib is a promising anticancer targeted agent for treating advanced carcinomas, such as non-small-cell lung cancer, small-cell lung cancer, breast cancer, malignant glioma, hepatocellular cancer, and unresectable, locally advanced, or metastatic medullary thyroid cancer. However, diarrhea is a frequently reported adverse event. The incidence of vandetanib-associated diarrhea varies extensively in different study populations and has not been carefully estimated. This systematic review and meta-analysis of clinical trials aims to figure out the overall risks of all-grade and high-grade diarrhea during vandetanib treatment and get a better understanding of its prediction and management. A comprehensive search was performed in EMBASE, PubMed, and Cochrane Library for clinical trials studying vandetanib and diarrhea prior to April 2015. Eligible articles were selected according to the inclusion criteria. Data were extracted to calculate the summary incidence of all-grade and high-grade diarrhea caused by vandetanib treatment. Thirteen clinical trials that involved 3,264 patients were included in this meta-analysis. The overall incidences of all-grade and high-grade diarrhea caused by vandetanib treatment were 52.1% (95% confidence interval [CI], 48.3%-55.8%) and 5.6% (95% CI, 4.4%-76.7%), respectively. The risk ratios of the all-grade and high-grade diarrhea for vandetanib arm versus control arm were 1.932 (95% CI, 1.746-2.138; P<0.001) and 3.190 (95% CI, 2.061-4.938; P<0.001), respectively. Studies with small-cell lung cancer demonstrated the highest incidence of all-grade diarrhea (78.85%) and high-grade diarrhea (17.31%), whereas the lowest incidences of all-grade (42.11%) and high-grade (2.67%) diarrhea are seen in patients with hepatocellular carcinoma and non-small-cell lung cancer, respectively. Our findings demonstrate that the administration of vandetanib leads to a significantly increased risk of diarrhea, which varies in different carcinoma patients. Early recognition and timely management may be key factors to avoid dose reduction, drug interruption, and drug discontinuation, which is significant to maximize the treatment benefits.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 14 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 3 21%
Student > Master 3 21%
Student > Postgraduate 2 14%
Researcher 2 14%
Other 1 7%
Other 3 21%
Readers by discipline Count As %
Medicine and Dentistry 6 43%
Unspecified 3 21%
Nursing and Health Professions 2 14%
Agricultural and Biological Sciences 2 14%
Sports and Recreations 1 7%
Other 0 0%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 August 2017.
All research outputs
#3,157,041
of 11,618,931 outputs
Outputs from OncoTargets and therapy
#124
of 1,322 outputs
Outputs of similar age
#83,912
of 267,202 outputs
Outputs of similar age from OncoTargets and therapy
#6
of 34 outputs
Altmetric has tracked 11,618,931 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,322 research outputs from this source. They receive a mean Attention Score of 2.5. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,202 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 34 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.